Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lu Si

Showing results (81-90 of 230) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Major response to everolimus in melanoma with acquired imatinib resistanceLu Si, Xiaowei Xu, Yan Kong, et al.
Virus Research|December 13, 2016
Substitution of the precursor peptide prevents anti-prM antibody-mediated antibody-dependent enhancement of dengue virus infectionYing Wang, Lu-Lu Si, Xiao-Lan Guo, et al.
Chinese Medical Journal|February 21, 2012
Role of C6ORF120, an N-glycosylated protein, is implicated in apoptosis of CD4⁺ T lymphocytesXin Li, Yong Qiao, Lu-Si Chang, et al.
Zhonghua Yi Xue Za Zhi|December 30, 2015
[Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma]Bixia Tang, Zhihong Chi, Xinan Sheng, et al.
Frontiers in Oncology|September 28, 2020
Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic MelanomaZhi-Long Wang, Li-Li Mao, Zhi-Guo Zhou, et al.
NPJ Genomic Medicine|February 5, 2021
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanomaChuanliang Cui, Canqiang Xu, Wenxian Yang, et al.
Cancer Medicine|December 10, 2015
Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trialsAgnieszka Malczewski, Andrea Marshall, Miranda J Payne, et al.
Cell Death & Disease|March 16, 2019
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinomaSifan Yu, Jie Dai, Meng Ma, et al.
Frontiers in Pharmacology|November 17, 2022
Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanomaQian Zhao, Teng Wang, Huanhuan Wang, et al.
Cancer Investigation|May 23, 2025
Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective AnalysisHuichun Tian, Jiaran Zhang, Lili Mao, et al.
Pageof 23

Showing results (81-90 of 230) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Major response to everolimus in melanoma with acquired imatinib resistanceLu Si, Xiaowei Xu, Yan Kong, et al.
Virus Research|December 13, 2016
Substitution of the precursor peptide prevents anti-prM antibody-mediated antibody-dependent enhancement of dengue virus infectionYing Wang, Lu-Lu Si, Xiao-Lan Guo, et al.
Chinese Medical Journal|February 21, 2012
Role of C6ORF120, an N-glycosylated protein, is implicated in apoptosis of CD4⁺ T lymphocytesXin Li, Yong Qiao, Lu-Si Chang, et al.
Zhonghua Yi Xue Za Zhi|December 30, 2015
[Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma]Bixia Tang, Zhihong Chi, Xinan Sheng, et al.
Frontiers in Oncology|September 28, 2020
Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic MelanomaZhi-Long Wang, Li-Li Mao, Zhi-Guo Zhou, et al.
NPJ Genomic Medicine|February 5, 2021
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanomaChuanliang Cui, Canqiang Xu, Wenxian Yang, et al.
Cancer Medicine|December 10, 2015
Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trialsAgnieszka Malczewski, Andrea Marshall, Miranda J Payne, et al.
Cell Death & Disease|March 16, 2019
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinomaSifan Yu, Jie Dai, Meng Ma, et al.
Frontiers in Pharmacology|November 17, 2022
Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanomaQian Zhao, Teng Wang, Huanhuan Wang, et al.
Cancer Investigation|May 23, 2025
Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective AnalysisHuichun Tian, Jiaran Zhang, Lili Mao, et al.
Pageof 23